Mobia Medical (MOBI) Q2 2026 earnings review
Hyper-Growth Top-Line, Widening Absolute Losses
Mobia Medical delivered a blowout quarter for revenue, accelerating 102% YoY to $13.5M on strong adoption of its Vivistim system. Despite facing macro tariff headwinds, gross margins expanded to 83.2%. However, the massive top-line growth is coming at a steep cost: operating expenses surged 83% to $29.2M as the company heavily funds its post-IPO commercial organization, driving net loss down to $21.0M. Armed with $177M in cash following a successful IPO, the company is aggressively scaling to meet FY26 guidance of $54-56M.
🐂 Bull Case
Sales doubled YoY, demonstrating exceptional product-market fit for Vivistim. H2 implied guidance ($29.4M midpoint) suggests sequential acceleration will continue.
The successful May IPO netted $134M, bringing cash to $177M. This completely removes any near-term liquidity overhang and fully funds the aggressive commercial rollout.
🐻 Bear Case
The net loss doubled YoY to $21.0M. While typical for an early-stage medtech, SG&A expenses are scaling massively ($26.9M this quarter) and will require sustained hyper-growth to eventually gain operating leverage.
Macroeconomic headwinds from freight and tariffs have emerged in COGS, partially capping what could have been even stronger gross margin expansion.
⚖️ Verdict: 🟢
Bullish. The 102% revenue growth and 83% gross margins prove the commercial viability of Vivistim. The widening operating loss is a strategic choice fully supported by the newly capitalized $177M balance sheet.
Key Themes
Vivistim Commercial Adoption
Revenue growth is Accelerating, up 102% YoY to $13.5M, heavily driven by increased adoption of the Vivistim System and higher IPG unit volumes. The company's expansion of its commercial footprint is yielding immediate top-line results.
Clinical Validation and Product Evidence
Mobia announced the publication of two-year VNS-REHAB follow-up data in Neurology®. This provides critical clinical validation for the Vivistim Paired VNS Therapy, demonstrating durable improvements in upper-limb motor function. This peer-reviewed evidence is a massive driver for ongoing provider adoption and reimbursement negotiations.
Gross Margin Resilience
Despite early-stage commercial scaling, gross margin is Stable and slightly improving, reaching 83.2% (up from 82.3% in Q2 2025). This proves the core unit economics of the implantable device are highly profitable before operating costs are factored in.
Negative Operating Leverage
Despite a stellar positive narrative on top-line and margins, the specific profitability data contradicts the optimism. Gross profit grew by $5.7M, but operating expenses surged by $13.2M (driven by SG&A expanding to $26.9M). The cost to acquire and service these new revenues is currently outpacing the gross margin dollars they generate, causing operating losses to Decelerate (worsen) to $17.9M.
Macro Freight and Tariff Impacts
Management explicitly cited freight and tariff costs hitting cost of goods sold (COGS) during the period. While other product/warranty efficiencies offset this to keep margins above 83%, escalating global trade tensions represent a clear macro risk to Mobia's supply chain and future margin profile.
Non-Operating Dilution and Fair Value Hits
Below the operating line, the company absorbed a $4.1M expense for the change in fair value of convertible notes payable. While standard for companies undergoing an IPO transition, it exacerbated the bottom-line net loss, and investors must monitor the new post-IPO share structure (weighted average shares jumped from 843K to 19.1M).
Other KPIs
Accelerating significantly, up 85% from $14.5 million in Q2 2025. This metric reflects the aggressive hiring of commercial personnel and commission expenses designed to capitalize on the Vivistim FDA approval.
A massive improvement from $33.6 million at year-end 2025, driven by $134.0 million in net proceeds from the May 2026 IPO. This war chest provides a multi-year runway to bridge the gap between heavy commercial burn and eventual break-even.
Guidance
Accelerating on an absolute basis, representing 69% to 75% YoY growth over FY25. With $25.6M secured in H1, the midpoint ($55.0M) implies H2 revenue of $29.4M. This indicates sequential half-over-half growth remains firmly intact.
Key Questions
Commercial Sales Productivity
SG&A increased by 85% this quarter to support the commercial organization. What is the average ramp time for a new sales rep to become fully productive, and what revenue-per-rep target are you aiming for in FY27?
Tariff and Supply Chain Exposure
You noted freight and tariff costs impacting COGS in Q2. What percentage of your raw materials or assembled components are sourced from tariff-affected regions, and do you have alternative sourcing plans to protect your 83%+ gross margin?
Path to Operating Leverage
With $177M in cash, liquidity is no longer a concern. However, operating expenses are growing faster than gross profit in absolute dollars. At what annualized revenue run-rate do you expect to see the inflection point where OPEX growth begins to trail revenue growth?